Brief Report: Outcomes of Individuals Using HIV Postexposure Prophylaxis-In-Pocket ("PIP") for Low-Frequency, High-Risk Exposures in Toronto, Canada

J Acquir Immune Defic Syndr. 2023 Nov 1;94(3):211-213. doi: 10.1097/QAI.0000000000003282.


Background: HIV postexposure prophylaxis-in-pocket ("PIP") is a self-initiated, event-driven HIV prevention modality for individuals with a low frequency of HIV exposures.

Methods: A cohort of 111 patients using PIP as their primary HIV prevention modality was longitudinally evaluated for PIP self-initiation, HIV and sexual transmitted infections, and switching to other HIV prevention modalities between February 2016 and December 2022.

Results: A total of 111 patients had 178.7 cumulative patient-years of PIP use. PIP was self-initiated 69 times by 35 (31.5%) individuals, with 0 HIV seroconversions identified. Thirty four individuals (30.6%) transitioned from PIP to pre-exposure prophylaxis and 33 individuals (29.7%) switched from pre-exposure prophylaxis to PIP.

Conclusions: PIP is a useful addition to other pharmacologic HIV prevention tools, and may help prevent infection in those with a lower frequency of unanticipated HIV exposures.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acquired Immunodeficiency Syndrome* / drug therapy
  • Anti-HIV Agents* / therapeutic use
  • Canada / epidemiology
  • HIV Infections* / drug therapy
  • HIV Infections* / prevention & control
  • Humans
  • Post-Exposure Prophylaxis
  • Pre-Exposure Prophylaxis*
  • Sexual Behavior


  • Anti-HIV Agents

Grants and funding